Cargando…

Intermittent administration of atezolizumab with combined carboplatin and etoposide therapy for patients with extensive‑disease small cell lung cancer

To the best of our knowledge, no published reports have examined the significance of additional immune checkpoint inhibitors in treating malignancies, including lung cancer. Therefore, the present study aimed to examine the efficacy and feasibility of adding atezolizumab to carboplatin and etoposide...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsuda, Takeshi, Imai, Hisao, Nagai, Yoshiaki, Umeda, Yukihiro, Shiono, Ayako, Shiihara, Jun, Yamaguchi, Ou, Mouri, Atsuto, Kaira, Kyoichi, Ishizuka, Tamotsu, Taniguchi, Hirokazu, Kagamu, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932630/
https://www.ncbi.nlm.nih.gov/pubmed/36817046
http://dx.doi.org/10.3892/ol.2023.13696
_version_ 1784889496071831552
author Tsuda, Takeshi
Imai, Hisao
Nagai, Yoshiaki
Umeda, Yukihiro
Shiono, Ayako
Shiihara, Jun
Yamaguchi, Ou
Mouri, Atsuto
Kaira, Kyoichi
Ishizuka, Tamotsu
Taniguchi, Hirokazu
Kagamu, Hiroshi
author_facet Tsuda, Takeshi
Imai, Hisao
Nagai, Yoshiaki
Umeda, Yukihiro
Shiono, Ayako
Shiihara, Jun
Yamaguchi, Ou
Mouri, Atsuto
Kaira, Kyoichi
Ishizuka, Tamotsu
Taniguchi, Hirokazu
Kagamu, Hiroshi
author_sort Tsuda, Takeshi
collection PubMed
description To the best of our knowledge, no published reports have examined the significance of additional immune checkpoint inhibitors in treating malignancies, including lung cancer. Therefore, the present study aimed to examine the efficacy and feasibility of adding atezolizumab to carboplatin and etoposide combination chemotherapy for small cell lung cancer with extensive disease (ED-SCLC). The present retrospective analysis examined 16 patients with ED-SCLC who received the addition of atezolizumab to carboplatin and etoposide therapy during treatment at four institutions between August 2019 and September 2020. The effectiveness of treatment was evaluated based on tumor response, survival time and adverse events. Within the study cohort, there were 14 males (87.5%) and 2 females (12.5%), with a median age of 73.5 years (range, 62–79 years); 7 patients had a performance status (PS) of 0–1 (43.8%) and 9 had a PS of 2–3 (56.3%). The median follow-up period was 12.1 months. The overall response rate, median progression-free survival time and median overall survival time were 75.0%, 5.3 and 13.0 months, respectively. Regarding the frequency of hematological adverse events, the occurrence of grade ≥3 adverse events was observed, including decreased neutrophil (56.3%), white blood cell (50.0%) and platelet (43.8%) counts, as well as febrile neutropenia (12.5%). Although 1 patient developed grade 3 pneumonitis as a serious adverse event, no treatment-related deaths were observed. Despite the aforementioned hematological toxicities, the addition of atezolizumab to carboplatin and etoposide therapy during treatment demonstrated favorable efficacy and acceptable toxicity in ED-SCLC. Thus, adding atezolizumab to carboplatin and etoposide combination chemotherapy may be a treatment option for ED-SCLC.
format Online
Article
Text
id pubmed-9932630
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-99326302023-02-17 Intermittent administration of atezolizumab with combined carboplatin and etoposide therapy for patients with extensive‑disease small cell lung cancer Tsuda, Takeshi Imai, Hisao Nagai, Yoshiaki Umeda, Yukihiro Shiono, Ayako Shiihara, Jun Yamaguchi, Ou Mouri, Atsuto Kaira, Kyoichi Ishizuka, Tamotsu Taniguchi, Hirokazu Kagamu, Hiroshi Oncol Lett Articles To the best of our knowledge, no published reports have examined the significance of additional immune checkpoint inhibitors in treating malignancies, including lung cancer. Therefore, the present study aimed to examine the efficacy and feasibility of adding atezolizumab to carboplatin and etoposide combination chemotherapy for small cell lung cancer with extensive disease (ED-SCLC). The present retrospective analysis examined 16 patients with ED-SCLC who received the addition of atezolizumab to carboplatin and etoposide therapy during treatment at four institutions between August 2019 and September 2020. The effectiveness of treatment was evaluated based on tumor response, survival time and adverse events. Within the study cohort, there were 14 males (87.5%) and 2 females (12.5%), with a median age of 73.5 years (range, 62–79 years); 7 patients had a performance status (PS) of 0–1 (43.8%) and 9 had a PS of 2–3 (56.3%). The median follow-up period was 12.1 months. The overall response rate, median progression-free survival time and median overall survival time were 75.0%, 5.3 and 13.0 months, respectively. Regarding the frequency of hematological adverse events, the occurrence of grade ≥3 adverse events was observed, including decreased neutrophil (56.3%), white blood cell (50.0%) and platelet (43.8%) counts, as well as febrile neutropenia (12.5%). Although 1 patient developed grade 3 pneumonitis as a serious adverse event, no treatment-related deaths were observed. Despite the aforementioned hematological toxicities, the addition of atezolizumab to carboplatin and etoposide therapy during treatment demonstrated favorable efficacy and acceptable toxicity in ED-SCLC. Thus, adding atezolizumab to carboplatin and etoposide combination chemotherapy may be a treatment option for ED-SCLC. D.A. Spandidos 2023-02-02 /pmc/articles/PMC9932630/ /pubmed/36817046 http://dx.doi.org/10.3892/ol.2023.13696 Text en Copyright: © Tsuda et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Tsuda, Takeshi
Imai, Hisao
Nagai, Yoshiaki
Umeda, Yukihiro
Shiono, Ayako
Shiihara, Jun
Yamaguchi, Ou
Mouri, Atsuto
Kaira, Kyoichi
Ishizuka, Tamotsu
Taniguchi, Hirokazu
Kagamu, Hiroshi
Intermittent administration of atezolizumab with combined carboplatin and etoposide therapy for patients with extensive‑disease small cell lung cancer
title Intermittent administration of atezolizumab with combined carboplatin and etoposide therapy for patients with extensive‑disease small cell lung cancer
title_full Intermittent administration of atezolizumab with combined carboplatin and etoposide therapy for patients with extensive‑disease small cell lung cancer
title_fullStr Intermittent administration of atezolizumab with combined carboplatin and etoposide therapy for patients with extensive‑disease small cell lung cancer
title_full_unstemmed Intermittent administration of atezolizumab with combined carboplatin and etoposide therapy for patients with extensive‑disease small cell lung cancer
title_short Intermittent administration of atezolizumab with combined carboplatin and etoposide therapy for patients with extensive‑disease small cell lung cancer
title_sort intermittent administration of atezolizumab with combined carboplatin and etoposide therapy for patients with extensive‑disease small cell lung cancer
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932630/
https://www.ncbi.nlm.nih.gov/pubmed/36817046
http://dx.doi.org/10.3892/ol.2023.13696
work_keys_str_mv AT tsudatakeshi intermittentadministrationofatezolizumabwithcombinedcarboplatinandetoposidetherapyforpatientswithextensivediseasesmallcelllungcancer
AT imaihisao intermittentadministrationofatezolizumabwithcombinedcarboplatinandetoposidetherapyforpatientswithextensivediseasesmallcelllungcancer
AT nagaiyoshiaki intermittentadministrationofatezolizumabwithcombinedcarboplatinandetoposidetherapyforpatientswithextensivediseasesmallcelllungcancer
AT umedayukihiro intermittentadministrationofatezolizumabwithcombinedcarboplatinandetoposidetherapyforpatientswithextensivediseasesmallcelllungcancer
AT shionoayako intermittentadministrationofatezolizumabwithcombinedcarboplatinandetoposidetherapyforpatientswithextensivediseasesmallcelllungcancer
AT shiiharajun intermittentadministrationofatezolizumabwithcombinedcarboplatinandetoposidetherapyforpatientswithextensivediseasesmallcelllungcancer
AT yamaguchiou intermittentadministrationofatezolizumabwithcombinedcarboplatinandetoposidetherapyforpatientswithextensivediseasesmallcelllungcancer
AT mouriatsuto intermittentadministrationofatezolizumabwithcombinedcarboplatinandetoposidetherapyforpatientswithextensivediseasesmallcelllungcancer
AT kairakyoichi intermittentadministrationofatezolizumabwithcombinedcarboplatinandetoposidetherapyforpatientswithextensivediseasesmallcelllungcancer
AT ishizukatamotsu intermittentadministrationofatezolizumabwithcombinedcarboplatinandetoposidetherapyforpatientswithextensivediseasesmallcelllungcancer
AT taniguchihirokazu intermittentadministrationofatezolizumabwithcombinedcarboplatinandetoposidetherapyforpatientswithextensivediseasesmallcelllungcancer
AT kagamuhiroshi intermittentadministrationofatezolizumabwithcombinedcarboplatinandetoposidetherapyforpatientswithextensivediseasesmallcelllungcancer